Fabrazyme (Genzyme Corporation)


Welcome to the PulseAid listing for the Fabrazyme drug offered from Genzyme Corporation. This alpha-Glucosidases [Chemical/Ingredient],Hydrolytic Lysosomal Neutral Glycosphingolipid-specific Enzyme [EPC] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: Genzyme Corporation
NON-PROPRIETARY NAME: AGALSIDASE BETA
SUBSTANCE NAME: AGALSIDASE BETA
TYPE: HUMAN PRESCRIPTION DRUG
PHARMA CLASS: alpha-Glucosidases [Chemical/Ingredient],Hydrolytic Lysosomal Neutral Glycosphingolipid-specific Enzyme [EPC]
ROUTE: INTRAVENOUS
DOSAGE FORM: INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
MARKETING CATEGORY NAME: BLA
START MARKETING DATE: 2008-12-17
END MARKETING DATE: 0000-00-00


Fabrazyme HUMAN PRESCRIPTION DRUG Details:

Item DescriptionFabrazyme from Genzyme Corporation
LABELER NAME: Genzyme Corporation
DEA SCHEDULE:
ACTIVE STRENGTH: 5(mg/mL)
START MARKETING DATE: 2008-12-17
END MARKETING DATE: 0000-00-00
PRODUCT ID: 58468-0040_1062d32d-80a0-43eb-b5fa-78c3ea27504e
PRODUCT NDC: 58468-0040
APPLICATION NUMBER: BLA103979

Other AGALSIDASE BETA Pharmaceutical Manufacturers / Labelers:

Manufacturer / LabelerProprietary Name
Genzyme CorporationFabrazyme